BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28105276)

  • 1. Covalent Guanosine Mimetic Inhibitors of G12C KRAS.
    Xiong Y; Lu J; Hunter J; Li L; Scott D; Choi HG; Lim SM; Manandhar A; Gondi S; Sim T; Westover KD; Gray NS
    ACS Med Chem Lett; 2017 Jan; 8(1):61-66. PubMed ID: 28105276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C.
    Hunter JC; Gurbani D; Ficarro SB; Carrasco MA; Lim SM; Choi HG; Xie T; Marto JA; Chen Z; Gray NS; Westover KD
    Proc Natl Acad Sci U S A; 2014 Jun; 111(24):8895-900. PubMed ID: 24889603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drugging K-Ras
    Ni D; Li X; He X; Zhang H; Zhang J; Lu S
    Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
    Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
    Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutant-Specific Targeting of Ras G12C Activity by Covalently Reacting Small Molecules.
    Goody RS; Müller MP; Rauh D
    Cell Chem Biol; 2019 Oct; 26(10):1338-1348. PubMed ID: 31378709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors.
    Stites EC; Shaw AS
    CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):342-351. PubMed ID: 29484842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
    Fell JB; Fischer JP; Baer BR; Ballard J; Blake JF; Bouhana K; Brandhuber BJ; Briere DM; Burgess LE; Burkard MR; Chiang H; Chicarelli MJ; Davidson K; Gaudino JJ; Hallin J; Hanson L; Hee K; Hicken EJ; Hinklin RJ; Marx MA; Mejia MJ; Olson P; Savechenkov P; Sudhakar N; Tang TP; Vigers GP; Zecca H; Christensen JG
    ACS Med Chem Lett; 2018 Dec; 9(12):1230-1234. PubMed ID: 30613331
    [No Abstract]   [Full Text] [Related]  

  • 9. Identification of the Clinical Development Candidate
    Fell JB; Fischer JP; Baer BR; Blake JF; Bouhana K; Briere DM; Brown KD; Burgess LE; Burns AC; Burkard MR; Chiang H; Chicarelli MJ; Cook AW; Gaudino JJ; Hallin J; Hanson L; Hartley DP; Hicken EJ; Hingorani GP; Hinklin RJ; Mejia MJ; Olson P; Otten JN; Rhodes SP; Rodriguez ME; Savechenkov P; Smith DJ; Sudhakar N; Sullivan FX; Tang TP; Vigers GP; Wollenberg L; Christensen JG; Marx MA
    J Med Chem; 2020 Jul; 63(13):6679-6693. PubMed ID: 32250617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
    Mortier J; Friberg A; Badock V; Moosmayer D; Schroeder J; Steigemann P; Siegel F; Gradl S; Bauser M; Hillig RC; Briem H; Eis K; Bader B; Nguyen D; Christ CD
    ChemMedChem; 2020 May; 15(10):827-832. PubMed ID: 32237114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of
    Shin Y; Jeong JW; Wurz RP; Achanta P; Arvedson T; Bartberger MD; Campuzano IDG; Fucini R; Hansen SK; Ingersoll J; Iwig JS; Lipford JR; Ma V; Kopecky DJ; McCarter J; San Miguel T; Mohr C; Sabet S; Saiki AY; Sawayama A; Sethofer S; Tegley CM; Volak LP; Yang K; Lanman BA; Erlanson DA; Cee VJ
    ACS Med Chem Lett; 2019 Sep; 10(9):1302-1308. PubMed ID: 31531201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel K-Ras G12C Switch-II Covalent Binders Destabilize Ras and Accelerate Nucleotide Exchange.
    Nnadi CI; Jenkins ML; Gentile DR; Bateman LA; Zaidman D; Balius TE; Nomura DK; Burke JE; Shokat KM; London N
    J Chem Inf Model; 2018 Feb; 58(2):464-471. PubMed ID: 29320178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Covalent inhibitors of the GTPase KRAS
    Kettle JG; Cassar DJ
    Expert Opin Ther Pat; 2020 Feb; 30(2):103-120. PubMed ID: 31913776
    [No Abstract]   [Full Text] [Related]  

  • 14. Modeling receptor flexibility in the structure-based design of KRAS
    Zhu K; Li C; Wu KY; Mohr C; Li X; Lanman B
    J Comput Aided Mol Des; 2022 Aug; 36(8):591-604. PubMed ID: 35930206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C.
    Zeng M; Lu J; Li L; Feru F; Quan C; Gero TW; Ficarro SB; Xiong Y; Ambrogio C; Paranal RM; Catalano M; Shao J; Wong KK; Marto JA; Fischer ES; Jänne PA; Scott DA; Westover KD; Gray NS
    Cell Chem Biol; 2017 Aug; 24(8):1005-1016.e3. PubMed ID: 28781124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor.
    Lim SM; Westover KD; Ficarro SB; Harrison RA; Choi HG; Pacold ME; Carrasco M; Hunter J; Kim ND; Xie T; Sim T; Jänne PA; Meyerson M; Marto JA; Engen JR; Gray NS
    Angew Chem Int Ed Engl; 2014 Jan; 53(1):199-204. PubMed ID: 24259466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proof of concept for poor inhibitor binding and efficient formation of covalent adducts of KRAS
    Khrenova MG; Kulakova AM; Nemukhin AV
    Org Biomol Chem; 2020 Apr; 18(16):3069-3081. PubMed ID: 32101243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRAS
    Luo L; Zheng T; Wang Q; Liao Y; Zheng X; Zhong A; Huang Z; Luo H
    Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
    Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
    Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.